61. Autoimmune hemolytic anemia Clinical trials / Disease details

Clinical trials : 146 / Drugs : 131 - (DrugBank : 59) / Drug target genes : 28 - Drug target pathways : 158

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2022-001773-31-ES (EUCTR)	14/02/2023	11/10/2022	A study of efficacy and safety of ianalumab in previously treated patients with warm autoimmune haemolytic aneamia	A phase 3, randomized, double-blind, study to assess efficacy and safety of ianalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed at least one line of treatment (VAYHIA) - VAYHIA	warm autoimmune haemolytic anaemia (wAIHA) MedDRA version: 25.0;Level: LLT;Classification code 10047822;Term: Warm type haemolytic anaemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]	Product Name: Ianalumab Product Code: VAY736 INN or Proposed INN: Ianalumab	Novartis Farmacéutica, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	90	Phase 3	Argentina;Singapore;Hungary;United States;Japan;United Kingdom;Malaysia;Thailand;Spain;India;China;Taiwan;Italy;Israel;Australia;France;Germany
2	NCT05648968 (ClinicalTrials.gov)	December 30, 2022	23/11/2022	A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia	A Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Who Failed at Least One Line of Treatment	Warm Autoimmune Hemolytic Anemia (wAIHA)	Biological: Ianalumab;Drug: Placebo	Novartis Pharmaceuticals	NULL	Recruiting	18 Years	N/A	All	90	Phase 3	Singapore